Q2 2025 Management View John P. Butler, CEO, reported that "we generated over $13 million in Vafseo revenue in Q2 with approximately $12 million in demand sales, a 55% increase over Q1." Butler ...

With Ador's lawsuit still ongoing, NewJeans may still be able to leave the label, and their decision not to appeal may have been in order to stay in the court's good graces. Entertainment lawyer ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

Discover how Vertex Pharmaceuticals achieved 12% Q2 2025 revenue growth with new launches like ALYFTREK, CASGEVY, & JOURNAVX.

Context Therapeutics Inc. (NASDAQ: CNTX) is one of the best penny stocks under $1 to buy now. Earlier in June, Context Therapeutics presented a Trial in Progress poster for its Phase 1 clinical ...

Methods: This Phase 1, open-label, multicenter, dose-escalation and dose-expansion study of ASP4396 is enrolling adult patients with locally advanced (unresectable) or metastatic solid tumors with ...